Evolution of Pain Intensity in Patients with Temporomandibular Disorder and / or Bruxism

Bastos Lopes C.¹, Amorim M.² . Quaresma MC.³, Caramês J.⁴
¹ Student of the Integrated Master in Dentistry, Faculty of Dentistry, University of Lisbon
² Dentist, Student of the Master’s Degree in Biostatistics and Biometrics at Universidade Aberta
³ Dentist, Invited Professor, Faculty of Dental Medicine, University of Lisbon
⁴ Dentist, Full Professor, Faculty of Dental Medicine, University of Lisbon

Introduction

Temporomandibular disorder (TMD) is the most common cause of orofacial pain of non-dental origin(1), and pain is the symptom most frequently associated with this type of dysfunction, along with functional limitation and joint noise(2,3). The literature suggests that about 60% of TMD patients are simultaneously diagnosed with bruxism(4).

For the elaboration and evaluation of the treatment plan, as well as for the establishment of priorities, a correct quantification of pain intensity is essential, and for that, tools have been developed over time, of which the Numerical Pain Scale stands out (END)(5). This scale, used worldwide, is associated with a better execution and ease of filling, thus helping to systematize the information collected, and several studies prove its validity and reliability(6,7).

The objective of this work is to evaluate the evolution of pain intensity using the Numerical Pain Scale, in patients diagnosed with TMD and / or Bruxism before and after conservative treatments.

Materials and methods

Type of longitudinal observational study retrospective to 5 years, carried out from records made in the period between 2015 and 2020, through the consultation of clinical files of patients at a university clinic. The sample consisted of 192 cases of patients diagnosed with TMD and / or Bruxism and who underwent treatments (Figure 1). The assessment of pain intensity was performed before and after treatments, using a one-dimensional pain recording scale – Numerical Scale (figure 2).

Results

For the elaboration and evaluation of the treatment plan, as well as for the establishment of priorities, a correct quantification of pain intensity is essential, and for that, tools have been developed over time, of which the Numerical Pain Scale stands out (END)(5). This scale, used worldwide, is associated with a better execution and ease of filling, thus helping to systematize the information collected, and several studies prove its validity and reliability(6,7).

The objective of this work is to evaluate the evolution of pain intensity using the Numerical Pain Scale, in patients diagnosed with TMD and / or Bruxism before and after conservative treatments.

Discussion

According to the characterization of the sample in relation to gender, it is possible to observe a higher prevalence of signs and symptoms associated with TMD and / or bruxism, in the female gender (80.2%), which is in accordance with the literature(8). In relation to the age group, the average age of the participants was 42.2 years (± 18.4), a value identical to that reported by other studies that found that the highest prevalence of this condition (TMD) was between 20 and 40 years(9).

In general, it is possible to observe a reduction in the intensity of pain, both in cases diagnosed with TMD and Bruxism, which goes against what is observed in the literature, where most patients achieved symptom relief with conservative therapy(10-12).

The present work emphasizes the importance of analyzing pain at peak, latent and current, in order to better characterize the levels of pain reported by patients, as well as to improve the conduct of therapy to be implemented in both pathologies.

Conclusion

There was a reduction in pain intensity after conservative treatment in patients diagnosed with TMD and Bruxism.

Clinical Implications

The pain scale proved to be a one-dimensional instrument for self-assessment of pain intensity, with good clinical applicability, for monitoring treatments for patients diagnosed with TMD and Bruxism. Conservative treatments seem to have a positive effect on painful symptoms.

References


Figure 1 - Charts of characterization of the total sample regarding the diagnosis of TMD and Bruxism

Table 1. Evolution of the intensity of pain levels (final - initial) in percentage according to the diagnosis of TMD. Wilcoxon test: * p <0.05; ** p <0.01; *** p <0.001.

Table 2. Evolution of the intensity of pain levels (final - initial) in percentage according to the diagnosis of Bruxism. Wilcoxon test: * p <0.05; ** p <0.01; *** p <0.001.

Figure 2. Representative image of the Numerical Scale (END) - (Normative Circular nº9, DGS, 2003)

Figure 3. Representative scheme of sample selection

Figure 4. Graphs representing the evolution of pain intensity (Peak Pain (upper extremity) and Latency Pain (circular marker) in the initial evaluation (before the gray treatment) and the final evaluation (after the blue treatment), in patients diagnosed with TMD and Bruxism.

Figure 5. Graphs representing the evolution of pain intensity (Peak Pain (upper extremity) and Latency Pain (circular marker) in the initial evaluation (before the gray treatment) and the final evaluation (after the blue treatment), in patients diagnosed with TMD and Bruxism.

Table 3. Evolution of the intensity of pain levels (final - initial) in percentage depending on the diagnosis of TMD. Wilcoxon test: * p <0.05; ** p <0.01; *** p <0.001.

Table 4. Evolution of the intensity of pain levels (final - initial) in percentage depending on the diagnosis of Bruxism. Wilcoxon test: * p <0.05; ** p <0.01; *** p <0.001.

Figure 6. Graphs representing the evolution of pain intensity (Peak Pain (upper extremity) and Latency Pain (circular marker) in the initial evaluation (before the gray treatment) and the final evaluation (after the blue treatment), in patients diagnosed with TMD and Bruxism.

Figure 7. Graphs representing the evolution of pain intensity (Peak Pain (upper extremity) and Latency Pain (circular marker) in the initial evaluation (before the gray treatment) and the final evaluation (after the blue treatment), in patients diagnosed with TMD and Bruxism.